This article is more than 5 years old. Information may no longer be current.
Penn State appoints cancer institute director
Click Here to Manage Email Alerts
Raymond J. Hohl, MD, has been appointed director of Penn State Hershey Cancer Institute effective March 1.
Hohl also will hold professorial positions in the departments of medicine and pharmacology.
“Dr. Hohl is a gifted cancer physician and researcher, with a demonstrated commitment to training the next generation of clinicians and scientists who will treat and help find cures for cancer,” Harold L. Paz, MD, MS, CEO of Penn State Hershey Medical Center and Health System said in a press release. “We are pleased that he has chosen to bring his comprehensive experience to Penn State Hershey and know that he will guide our cancer institute to new heights of patient-centered, research-focused excellence.”
Hohl currently holds the Holden family chair and is associate chair of the department of internal medicine at the University of Iowa Carver College of Medicine. He also is associate director for clinical and translational research in the Holden Comprehensive Cancer Center at the University of Iowa.
Hohl’s research focuses on the discovery and development of novel anticancer therapies, ranging from basic laboratory studies to innovative human clinical trials. His research has been well-supported by grants from the NIH, Roy J. Carver Charitable Trust, Department of Defense, Leukemia and Lymphoma Society and the American Institute for Cancer Research.
A reviewer for numerous journals, Hohl currently serves as associate editor for the Nature journal Clinical Pharmacology and Therapeutics and is on the editorial advisory board of Lipids. Hohl also is an inventor for two key patents related to his research and is co-founder and president of Terpenoid Therapeutics, a biotechnology company.